CD8A and neoplasm: Differently from C20-ID, the C20-IM vaccine protocol resulted in a CD8+IFN+ effector memory (Fig. 3A and Supplementary Fig. 6A), and in the therapeutic treatment with αCTLA-4/C20-IM resulted in long-lasting regression of the CT26 tumor model (Fig. 5B).